- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANO HEALTH Aktie jetzt für 0€ handeln | |||||
| 20.10.25 | Ex-Cano Health CEO on Trial Amid $72M Fraud Claims | 3 | MedCity News |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 229,55 | +0,48 % | UNITEDHEALTH GROUP INC im analytischen Fokus | ||
| INTUITIVE SURGICAL | 399,35 | +1,09 % | Intuitive Surgical (ISRG) Stock Up After Jim Cramer Said To Just Go Buy It | ||
| THERMO FISHER | 423,05 | +0,97 % | THERMO FISHER SCIENTIFIC INC im strukturellen Gleichgewicht | ||
| ROKU | 78,11 | +1,45 % | Aurzen Official: Aurzen Announces Big Spring Sale for Aurzen Roku TV Smart Projectors | Designed to simplify both performance and usability, with a built-in Roku TV OS, Aurzen Roku TV Smart Projectors allow users to access thousands of streaming channels and apps instantly-without external... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update | SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 27,800 | +0,16 % | Centene ernennt Theodore Pienkos zum neuen Chief Accounting Officer und Controller | ||
| QUIDELORTHO | 13,400 | +1,52 % | QuidelOrtho Corporation: Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer | SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment... ► Artikel lesen | |
| VERU | 2,130 | +2,40 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,550 | 0,00 % | Tempest Therapeutics: Tempest Reports Year End 2025 Financial Results and Provides Business Update | Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing... ► Artikel lesen | |
| NANO-X IMAGING | 2,210 | 0,00 % | Nano-X Imaging Ltd: Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina | Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging... ► Artikel lesen | |
| FULGENT GENETICS | 13,800 | +0,73 % | Fulgent Genetics completes $56.9M pathology lab acquisitions | ||
| LANTHEUS | 64,58 | +1,22 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection | New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,300 | -1,20 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results | Lead program VMT-a-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 16,100 | +4,55 % | AMN Healthcare Services Inc: AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results | Quarterly revenue of $748 million- GAAP loss of ($0.20)/share and adjusted EPS of $0.22DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen |
Das Unternehmen CANO HEALTH INC kann der Branche Gesundheitswesen zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANO HEALTH INC finden Sie auf Wallstreet Online.